This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Tatsumi, T. Articles by Hayashi, N. Search for Related Content PubMed PubMed Citation Articles by Tatsumi, T. Articles by Hayashi, N.

Administration of Interleukin-12 Enhances the Therapeutic Efficacy of Dendritic Cell-based Tumor Vaccines in Mouse Hepatocellular Carcinoma¹

Departments of Internal Medicine and Therapeutics [T. Tat., T. Tak., T. K., M. H.], Molecular Therapeutics [T. M., N. K., Y. Su., M. J., Y. Sa., N. H.], and General Medicine [A. K.], Osaka University Graduate School of Medicine, Osaka 565-0871, Japan

Dendritic cells (DCs) are potent antigen-presenting cells that are capable of priming systemic antitumor immune response. Here, we evaluated the combined effectiveness of tumor lysate-pulsed DC immunization and interleukin (IL)-12 administration on the induction of antitumor immunity in a mouse hepatocellular carcinoma (HCC) model. Mouse DCs were pulsed with lysate of BNL 1ME A.7R.1 (BNL), a BALB/c-derived HCC cell line, and then injected into syngeneic mice in combination with systemic administration of IL-12. Lymphocytes from mice treated with BNL lysate-pulsed DCs and IL-12 showed stronger cytolytic activity and produced higher amounts of IFN- than those from mice treated with BNL lysate-pulsed DCs alone. Although immunization with BNL lysate-pulsed DCs alone did not lead to complete regression of established tumors, it significantly inhibited tumor growth compared with vehicle injection. Importantly, the combined therapy of BNL lysate-pulsed DCs and IL-12 resulted in tumor rejection or significant inhibition of tumor growth compared with mice treated with BNL lysate-pulsed DCs alone. In vivo lymphocyte depletion experiments demonstrated that this combination was dependent on both CD8⁺ and CD4⁺ T cells, but not natural killer cells. These results demonstrated that IL-12 administration enhanced the therapeutic effect of immunization of tumor lysate-pulsed DCs against HCC in mice. This combination of IL-12 and DCs may be useful for suppressing the growth of residual tumor after primary therapy of human HCC.

This article has been cited by other articles:

				N. Ohta, Y. Ohashi, and Y. Fujino Ketamine Inhibits Maturation of Bone Marrow-Derived Dendritic Cells and Priming of the Th1-Type Immune Response Anesth. Analg., September 1, 2009; 109(3): 793 - 800. [Abstract] [Full Text] [PDF]

				M. Y. Gerner, K. A. Casey, and M. F. Mescher Defective MHC Class II Presentation by Dendritic Cells Limits CD4 T Cell Help for Antitumor CD8 T Cell Responses J. Immunol., July 1, 2008; 181(1): 155 - 164. [Abstract] [Full Text] [PDF]

				A. H. Lau, M. Abe, and A. W. Thomson Ethanol affects the generation, cosignaling molecule expression, and function of plasmacytoid and myeloid dendritic cell subsets in vitro and in vivo J. Leukoc. Biol., May 1, 2006; 79(5): 941 - 953. [Abstract] [Full Text] [PDF]

				E. Belnoue, C. Guettier, M. Kayibanda, S. Le Rond, A.-M. Crain-Denoyelle, C. Marchiol, M. Ziol, D. Fradelizi, L. Renia, and M. Viguier Regression of Established Liver Tumor Induced by Monoepitopic Peptide-Based Immunotherapy J. Immunol., October 15, 2004; 173(8): 4882 - 4888. [Abstract] [Full Text] [PDF]

				M. Matsui, O. Moriya, M. L. Belladonna, S. Kamiya, F. A. Lemonnier, T. Yoshimoto, and T. Akatsuka Adjuvant Activities of Novel Cytokines, Interleukin-23 (IL-23) and IL-27, for Induction of Hepatitis C Virus-Specific Cytotoxic T Lymphocytes in HLA-A*0201 Transgenic Mice J. Virol., September 1, 2004; 78(17): 9093 - 9104. [Abstract] [Full Text] [PDF]

				P. Mandrekar, D. Catalano, A. Dolganiuc, K. Kodys, and G. Szabo Inhibition of Myeloid Dendritic Cell Accessory Cell Function and Induction of T Cell Anergy by Alcohol Correlates with Decreased IL-12 Production J. Immunol., September 1, 2004; 173(5): 3398 - 3407. [Abstract] [Full Text] [PDF]

				K. Teramoto, K. Kontani, Y. Ozaki, S. Sawai, N. Tezuka, T. Nagata, S. Fujino, Y. Itoh, O. Taguchi, Y. Koide, et al. Deoxyribonucleic Acid (DNA) Encoding a Pan-Major Histocompatibility Complex Class II Peptide Analogue Augmented Antigen-specific Cellular Immunity and Suppressive Effects on Tumor Growth Elicited by DNA Vaccine Immunotherapy Cancer Res., November 15, 2003; 63(22): 7920 - 7925. [Abstract] [Full Text] [PDF]

				K. Tschoep, T. C. Manning, H. Harlin, C. George, M. Johnson, and T. F. Gajewski Disparate functions of immature and mature human myeloid dendritic cells: implications for dendritic cell-based vaccines J. Leukoc. Biol., July 1, 2003; 74(1): 69 - 80. [Abstract] [Full Text] [PDF]

				P. Velupillai, J. P. Carroll, and T. L. Benjamin Susceptibility to Polyomavirus-Induced Tumors in Inbred Mice: Role of Innate Immune Responses J. Virol., August 28, 2002; 76(19): 9657 - 9663. [Abstract] [Full Text] [PDF]